Medexus Pharmaceuticals Inc (MDP)

Currency in CAD
2.62
-0.11(-4.03%)
Real-time Data·
MDP Scorecard
Full Analysis
Net income is expected to grow this year
MDP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.622.75
52 wk Range
1.715.56
Key Statistics
Bid/Ask
2.63 / 2.65
Prev. Close
2.73
Open
2.75
Day's Range
2.62-2.75
52 wk Range
1.71-5.56
Volume
21.06K
Average Volume (3m)
34.22K
1-Year Change
20.26%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MDP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.11
Upside
+171.37%
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Medexus Pharmaceuticals Inc Company Profile

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2018 and is based in Toronto, Canada.

Employees
91
Market
Canada

Medexus Pharmaceuticals Inc Earnings Call Summary for Q4/2025

  • Q4 revenue declined to $24.8M from $26M YoY, but full-year adjusted EBITDA hit record $20.2M
  • Grafifex launch shows promise with $600K Q4 revenue; expected to be cash flow accretive by Q4 2026
  • Stock price rose 2.13% post-earnings; analysts bullish with price targets up to $7.31
  • Base franchises expected to remain flat or slightly decline as company invests in Grafifex commercialization
  • CEO expresses confidence in Grafifex becoming standard of care in transplant market, citing strong demand and pricing
Last Updated: 26/06/2025, 14:04
Read Full Transcript

Compare MDP to Peers and Sector

Metrics to compare
MDP
Peers
Sector
Relationship
P/E Ratio
28.5x−0.3x−0.5x
PEG Ratio
0.030.000.00
Price/Book
1.2x0.5x2.6x
Price / LTM Sales
0.6x1.4x3.3x
Upside (Analyst Target)
119.8%39.6%43.4%
Fair Value Upside
Unlock12.9%7.1%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.11
(+171.37% Upside)

Earnings

Latest Release
Jun 25, 2025
EPS / Forecast
-0.02 / --
Revenue / Forecast
24.75M / 42.87M
EPS Revisions
Last 90 days

MDP Income Statement

FAQ

What Stock Exchange Does Medexus Pharma Trade On?

Medexus Pharma is listed and trades on the Toronto Stock Exchange stock exchange.

What Is the Stock Symbol for Medexus Pharma?

The stock symbol for Medexus Pharma is "MDP."

What Is the Medexus Pharma Market Cap?

As of today, Medexus Pharma market cap is 85.48M.

What Is Medexus Pharma's Earnings Per Share (TTM)?

The Medexus Pharma EPS (TTM) is 0.09.

From a Technical Analysis Perspective, Is MDP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Medexus Pharma Stock Split?

Medexus Pharma has split 2 times.

How Many Employees Does Medexus Pharma Have?

Medexus Pharma has 91 employees.

What is the current trading status of Medexus Pharma (MDP)?

As of 08 Aug 2025, Medexus Pharma (MDP) is trading at a price of 2.62, with a previous close of 2.73. The stock has fluctuated within a day range of 2.62 to 2.75, while its 52-week range spans from 1.71 to 5.56.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.